ETHYL 4-(2-(P-TOLYLOXY)HEXYLOXY)BENZOATE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	FOWOENOZRFMQMY-UHFFFAOYSA-N
Smiles	CCCCC(COc1ccc(cc1)C(=O)OCC)Oc2ccc(C)cc2
InChI	InChI=1S/C22H28O4/c1-4-6-7-21(26-20-12-8-17(3)9-13-20)16-25-19-14-10-18(11-15-19)22(23)24-5-2/h8-15,21H,4-7,16H2,1-3H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C22H28O4
Molecular Weight	356.46
AlogP	5.95
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	11.0
Polar Surface Area	44.76
Molecular species	None
Aromatic Rings	2.0
Heavy Atoms	26.0

Assay Description	Organism	Bioactivity
Induction of precocious metamorphosis in newly molted fourth-instar larvae of Bombyx mori assessed as precocious metamorphosis measured after topical treatment	Bombyx mori	None
Induction of precocious metamorphosis in 24 hr old third-instar larvae of Bombyx mori assessed as precocious metamorphosis at 40 ug/larva topically by antijuvenile hormone activity assay	Bombyx mori	58.0 %
Induction of precocious metamorphosis in 24 hr old third-instar larvae of Bombyx mori assessed as precocious metamorphosis at 10 ug/larva topically by antijuvenile hormone activity assay	Bombyx mori	45.0 %
Induction of precocious metamorphosis in 24 hr old third-instar larvae of Bombyx mori assessed as precocious metamorphosis at 1 ug/larva topically by antijuvenile hormone activity assay	Bombyx mori	5.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2269894
PubChem	71422970

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).